Table 2.

Demographic and clinical characteristics of patients in the anti-TNF and stem cell groups

	Anti-TNF (n=39)	Stem cell (n=30)	p-value
Age, median (IQR)	31.0 (25-34)	26.0 (20-30.25)	0.028
Sex
Male	29 (74.4%)	14 (46.7%)	0.019
Female	10 (25.6%)	16 (53.3%)
Montreal classification
Age at onset
A1 (≤16yr)	15 (38.5%)	6 (20.0%)	0.098
A2 (17-40yr)	24 (61.5%)	24 (80.0%)
A3 (≥41yr)	0 (0.0%)	0 (0.0%)
Location
L1 (Ileum)	4 (10.3%)	8 (26.7%)	0.171
L2 (Colon)	3 (7.7%)	3 (10.0%)
L3 (Ileocolon)	32 (82.1%)	19 (63.3%)
Behavior
B1 (Non-stricturing, non-penetrating)	12 (30.8%)	20 (66.7%)	0.002
B2 (Stricturing)	6 (15.4%)	6 (20.0%)
B3 (Penetrating)	21 (53.8%)	4 (13.3%)
Albumin, mean±SD (g/dL)	3.36±0.48	4.05±0.42	<0.001
CRP, mean±SD (mg/dL)	3.03±3.04	0.56±0.74	<0.001
Fistula type
Simple	13 (33.3%)	6 (20.0%)	0.219
Complex	26 (66.7%)	24 (80.0%)
Multiple fistula	15 (38.5%)	13 (43.3%)	0.683
Proctitis	19 (48.7%)	10 (33.3%)	0.199
Stricture	1 (2.6%)	2 (6.7%)	0.407
Abscess	18 (46.2%)	17 (56.7%)	0.387
Medical treatment
Immunomodulators	16 (41.0%)	15 (50.0%)	0.458
Steroids	2 (5.2%)	0 (0.0%)	0.208
Smoking
Current smoker	4 (10.3%)	1 (3.3%)	0.355
Ex-smoker	8 (20.5%)	4 (13.3%)
Previous fistula OP	37 (94.9%)	30 (100%)	0.208
No. previous fistula OP, mean±SD (times)	3.24±1.89	2.17±1.29	0.010
Interval from seton treatment to anti-TNF or stem cell therapy, mean±SD (months)	1.03±0.93	16.13±16.01	<0.001
Disease duration, mean±SD (years)	9.37±6.13	6.10±4.88	0.018

Results are presented as n (%) unless otherwise indicated.

IQR Inter-quartile range, TNF tumor necrosis factor, SD Standard deviation, CRP C-reactive protein, OP operation